Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 83 | 0.91 |
| pathways Reactome | 1 pathway; mostly lysosome and autophagy | 1.00 |
No case: the score is under the bar. Receipt 14238
Sealed predictions
- ATG4D in dopamine neurons, braak-0.08 (p 0.838) → -0.51 (p 0.157)receipt 14246
Swarm cases
receipt 14246: ATG4D in dopamine neurons, braak
- power
- full sample -0.45 (p 0.059, n 18), 95% CI -0.76 to +0.02. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.47 (p 0.050, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.46 (p 0.052, n 18). could be the mix.
- skeptic
- leave-one-out range -0.56 to -0.38, sign flips 0; without severely affected donors -0.45 (p 0.059, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ATG4D in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts